Back to Journals » Patient Related Outcome Measures » Volume 9

Immune thrombocytopenia: improving quality of life and patient outcomes

Authors Trotter P, Hill QA

Received 25 August 2018

Accepted for publication 19 October 2018

Published 27 November 2018 Volume 2018:9 Pages 369—384

DOI https://doi.org/10.2147/PROM.S140932

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Dr Robert Howland


Patrick Trotter,1,2 Quentin A Hill3

1Department of Surgery, University of Cambridge, Cambridge, UK; 2National Health Service Blood and Transplant, Organ Donation and Transplant Directorate, Bristol, UK; 3Department of Haematology, St James’s University Hospital, Leeds, UK

Abstract: Immune thrombocytopenia (ITP) is an immune-mediated disorder characterized by a reduced platelet count and patients may develop bruising or mucosal bleeding. Since 2003, generic health-related quality of life (HRQoL) measures have been applied and ITP-specific measures developed, alongside trials of novel therapeutic agents. These have identified significant morbidity in patients with ITP, including fatigue, fear of bleeding and a negative impact on role, social and work activities. This review critically evaluates HRQoL data in adults and children with ITP. It also considers the impact of treatment and how patient-reported outcomes might be applied to care to optimize patients’ quality of life.

Keywords:
immune thrombocytopenia, quality of life, fatigue, eltrombopag, romiplostim, bleeding, SF-36, KIT, depression, ITP-PAQ

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]